The global ovarian cancer drugs market expected to reach US$ 3.8 billion by 2021, growing at CAGR 20.5% over the forecast period 2017-2021, mainly due to continued uptake and expected launch of approved PARP inhibitors, and owing to their impressive efficacy, long treatment duration and large number of treatment opportunities in the first-line advanced settings.
Ovarian cancer is a cancer that forms in or on an ovary. In 2015, it was present in 1.2 million women and resulted in 161,100 deaths worldwide. The risk of ovarian cancer increases in women who have ovulated more over their lifetime. A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery. Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Chemotherapy in ovarian cancer typically consists of platins, a group of platinum-based drugs, combined with non-platins. Common therapies can include paclitaxel, cisplatin, topotecan, doxorubicin, epirubicin, and gemcitabine. The vascular endothelial growth factor (VEGF) inhibitor, bevacizumab (Avastin; Roche/ Genentech), is approved (excluding the United States) as a first-line treatment in combination with standard chemotherapy. In Europe and the United States, bevacizumab is also approved for recurrent ovarian cancer.
Browse Ovarian Cancer Drugs Market by Drug Class (Angiogenesis inhibitors, Poly (ADP Ribose) Polymerase Inhibitors, Programmed Cell Death Protein 1 Ligand 1 Inhibitors), Pipeline Analysis by Target and Development Stage and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/
The global ovarian cancer drugs market segmentation is based on drug class (angiogenesis inhibitors, poly (ADP ribose) polymerase inhibitors, programmed cell death protein 1 ligand 1 inhibitors), and pipeline analysis by target and development stage.
The global ovarian cancer drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global ovarian cancer drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LATAM), and Rest of the World. The global ovarian cancer drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global ovarian cancer drugs market and profiled in this report include AbbVie, AstraZeneca (Acerta Pharma), Boehringer Ingelheim GmbH, Five Prime Therapeutics, Gradalis, Incyte Corporation, MacroGenics, Mateon Therapeutics, Merck KGaA, Novartis, Novogen, Inc., Oasmia Pharmaceuticals, Pfizer, Inc., PharmaMar (Chugai), and Roche (Genentech).
- Drug Class
- Angiogenesis inhibitors
- Poly (ADP Ribose) Polymerase (PARP) Inhibitors
- Programmed Cell Death Protein 1 Ligand 1 (PDL1) Inhibitors
- Pipeline Analysis by Target and Development Stage
- Geography (Region, Country)
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LATAM)
- Rest of the World
- Company Profiles
- AstraZeneca (Acerta Pharma)
- Boehringer Ingelheim GmbH
- Five Prime Therapeutics
- Incyte Corporation
- Mateon Therapeutics
- Merck KGaA
- Oasmia Pharmaceuticals
- Pfizer, Inc.
- PharmaMar (Chugai)
- Roche (Genentech)
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043